Carl Icahn has determined to not launch a contemporary proxy struggle at DNA sequencing firm Illumina Inc. this 12 months, an individual aware of the matter mentioned.
The activist investor didn’t nominate administrators for seats on the board of Illumina earlier than a deadline to take action handed, the individual mentioned, asking to not be recognized discussing confidential info.
A consultant for Illumina declined to remark, whereas a spokesperson for Icahn Enterprises LP couldn’t instantly be reached for remark. Icahn’s choice was reported earlier on Tuesday by Reuters.
Icahn thought-about nominating as many as seven candidates at Illumina, Bloomberg Information reported in December, after blaming the corporate’s administration for its dealing with of the failed acquisition of most cancers detection startup Grail Inc.
Final 12 months, the activist succeeded in having his nominee Andrew Teno elected to Illumina’s board.
